eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2022
vol. 73
 
Share:
Share:
more
 
 
abstract:
Original paper

Predictive value of ALDH1 and CD44 positivity for radiotherapy response and prognosis in early-stage glottic laryngeal squamous cell carcinoma

Ozgur Surmelioglu
1
,
Kıvılcım Eren Erdogan
2
,
Muhammed Dagkiran
1
,
Suleyman Ozdemir
1
,
Ozgur Tarkan
1
,
Aysun Uguz
2

1.
Department of Otorhinolaryngology, Faculty of Medicine, Cukurova University, Adana, Turkey
2.
Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey
Pol J Pathol 2022; 74 (1): 43-49
Online publish date: 2022/06/29
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
To evaluate the predictive value of CD44 and aldehyde dehydrogenase 1 (ALDH1) expression for prognosis and radiotherapy (RT) response in patients with early-stage laryngeal cancer receiving RT.

Forty-four patients with early-stage laryngeal cancer diagnosed between 2002 and 2016 were included in the study. The correlation between RT response and pre-treatment immunohistochemical ALDH1 and CD44 staining was evaluated. In addition, survival times were compared between groups.

The mean age of the 44 patients was 59.8 ±9.0 (43-81) years and 41 were male. There were 20 patients in the non-recurrent group (all men) and 24 patients in the recurrent group (21 men). Immunohistochemical positivity for ALDH1 was found to be a significant risk factor for RT failure (p = 0.0001), whereas CD44 positivity (p = 0.114) and age group (p = 0.287) were not significant.

ALDH1 positivity was identified as a significant predictor of DFS and RT sensitivity, while CD44 positivity did not differ according to RT response.
keywords:

laryngeal squamous cell carcinoma, ALDH1, CD44, radiotherapy

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.